LT4/LT3 Combination Therapy vs. Monotherapy with LT4 for Persistent Symptoms of Hypothyroidism: A Systematic Review

被引:0
|
作者
Vargas-Uricoechea, Hernando [1 ]
Wartofsky, Leonard [2 ]
机构
[1] Univ Cauca, Dept Internal Med, Metab Dis Study Grp, Carrera 6 13N-50, Popayan 190001, Colombia
[2] Georgetown Univ, Sch Med, Medstar Hlth Res Inst, Washington, DC 20007 USA
关键词
hypothyroidism; persistent symptoms; levothyroxine; L-triiodothyronine; therapy; QUALITY-OF-LIFE; LEVOTHYROXINE PLUS LIOTHYRONINE; THYROID-HORMONE REPLACEMENT; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; THYROXINE T-4; DEPRESSIVE SYMPTOMS; TRIIODOTHYRONINE; EXTRACT; 3,5,3'-TRIIODOTHYRONINE;
D O I
10.3390/ijms25179218
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Regardless of the cause, hypothyroidism should be treated with levothyroxine. The objectives of management are the normalization of TSH levels and the relief of symptoms. In general, the vast majority of patients who achieve normalization of TSH levels show a resolution of symptoms; however, for a small number of individuals, symptoms persist (despite adequate control of TSH). This scenario generates a dilemma in the therapeutic approach to these patients, because even when excluding other causes or concomitant diseases that can explain the persistence of symptoms, pharmacological management strategies are scarce. Consequently, the efficacy of some less conventional approaches to therapy, such as the use of LT3 monotherapy, desiccated thyroid extracts, and LT4/LT3 combinations, in addressing persistent hypothyroid symptoms have been evaluated in multiple studies. The majority of these studies did not observe a significant benefit from these "nonconventional" therapies in comparison to results with LT4 monotherapy alone. Nevertheless, some studies report that a significant proportion of patients prefer an alternative to monotherapy with LT4. The most common approach has been to prescribe a combination of LT4 and LT3, and this review describes and analyzes the current evidence of the efficacy of LT4/LT3 combination therapy vs. LT4 monotherapy in addressing persistent hypothyroidism symptoms to provide suggested guidelines for clinicians in the management of these patients.
引用
收藏
页数:15
相关论文
共 36 条
  • [31] Can Reverse T3 Assay Be Employed to Guide T4 vs. T4/T3 Therapy in Hypothyroidism?
    Gomes-Lima, Cristiane
    Wartofsky, Leonard
    Burman, Kenneth
    FRONTIERS IN ENDOCRINOLOGY, 2019, 10
  • [32] Effect of combination therapy with thyroxine (T4) and 3,5,3′-triiodothyronine versus T4 monotherapy in patients with hypothyroidism, a double-blind, randomised cross-over study
    Nygaard, Birte
    Jensen, Ebbe Winther
    Kvetny, Jan
    Jarlov, Anne
    Faber, Jens
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 161 (06) : 895 - 902
  • [33] Peripheral markers of thyroid function: the effect of T4 monotherapy vs T4/T3 combination therapy in hypothyroid subjects in a randomized crossover study
    Schmidt, Ulla
    Nygaard, Birte
    Jensen, Ebbe Winther
    Kvetny, Jan
    Jarlov, Anne
    Faber, Jens
    ENDOCRINE CONNECTIONS, 2013, 2 (01) : 56 - 61
  • [34] Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis
    Foroutan, Naghmeh
    Muratov, Sergei
    Levine, Mitchell
    CLINICAL AND INVESTIGATIVE MEDICINE, 2016, 39 (02): : E48 - E62
  • [35] Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
    Scheen, A. J.
    DIABETES & METABOLISM, 2020, 46 (03) : 186 - 196
  • [36] Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis
    Zheng, Jiani
    Wu, Jingxun
    Wang, Chunyue
    Zhuang, Shiwen
    Chen, Jianbo
    Ye, Feng
    PLOS ONE, 2020, 15 (06):